¼¼°èÀÇ À¯ÀüÀÚ ºÐ¼® ½ÃÀå
Genetic Analysis
»óǰÄÚµå : 1791861
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 580 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,245,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,736,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ À¯ÀüÀÚ ºÐ¼® ½ÃÀåÀº 2030³â±îÁö 165¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 116¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ À¯ÀüÀÚ ºÐ¼® ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 6.1%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 165¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ ½Ã¾à & ŰƮ´Â CAGR 6.6%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á±îÁö 94¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±â±â ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ Áß CAGR 4.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº ÃßÁ¤ 32¾ï ´Þ·¯, Áß±¹Àº CAGR 9.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ À¯ÀüÀÚ ºÐ¼® ½ÃÀåÀº 2024³â¿¡ 32¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 34¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 9.6%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.9%¿Í 6.0%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ À¯ÀüÀÚ ºÐ¼® ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

À¯ÀüÀÚ ºÐ¼®ÀÌ ÇコÄɾî¿Í °úÇÐ ¿¬±¸¿¡ Çõ¸íÀ» °¡Á®¿Ã ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

À¯ÀüÀÚ ºÐ¼®Àº DNA ¼­¿­, À¯ÀüÀÚ º¯ÀÌ, Áúº´ ¼ÒÀο¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÔÀ¸·Î½á ÇコÄɾî, ³ó¾÷, »ý¹° ÀÇÇÐ ¿¬±¸¿¡ º¯È­¸¦ °¡Á®¿Ô½À´Ï´Ù. Â÷¼¼´ë ½ÃÄö½Ì(NGS), ÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ(PCR), ¸¶ÀÌÅ©·Î¾î·¹ÀÌ ±â¼úÀÇ ¹ßÀüÀ¸·Î ¿¬±¸ÀÚµéÀº Àü·Ê ¾ø´Â Á¤È®µµ¿Í ¼Óµµ·Î À¯ÀüÁ¤º¸¸¦ ÇØµ¶ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº À¯Àü¼º ÁúȯÀÇ ½Äº°, ¾ÏÀÇ Á¶±â ¹ß°ß, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ Á¢±ÙÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ȯÀÚ Ä¡·á¿Í Áúº´ °ü¸®¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ ºÐ¼®Àº ÇコÄɾî»Ó¸¸ ¾Æ´Ï¶ó ¹ýÀÇÇÐ, ÁøÈ­»ý¹°ÇÐ, ³ó¾÷ ºÐ¾ß¿¡¼­µµ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¹ýÀÇÇÐ ¼ö»ç¿¡¼­´Â DNA ÇÁ·ÎÆÄÀϸµÀÌ ¹üÁË ÇØ°á ´É·ÂÀ» Çâ»ó½Ã۰í, ³ó¾÷¿¡¼­´Â À¯ÀüÀÚ ºÐ¼®ÀÌ °í¸ÅÃâ°ú Áúº´¿¡ °­ÇÑ ÀÛ¹° À°Á¾À» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ D2C À¯ÀüÀÚ °Ë»ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¶»ó, °Ç°­ À§Çè, À¯ÀüÇüÁú¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ¾òÀ» ¼ö ÀÖ°Ô µÇ¾î ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ºÐ¼®ÀÇ ¿ëµµ°¡ °è¼Ó È®´ëµÊ¿¡ µû¶ó ¿©·¯ »ê¾÷ ºÐ¾ß¿¡¼­ °í󸮷® ½ÃÄö½Ì ¹× ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ ºÐ¼® ¼ö¿ä¸¦ ÁÖµµÇÏ´Â »ê¾÷Àº?

ÇコÄÉ¾î ºÐ¾ß´Â À¯Àüü ºÐ¼® ±â¼úÀÇ °¡Àå Å« ¼ÒºñÀÚÀ̸ç, Áúº´ À§Çè Æò°¡, Á¤¹ÐÀÇ·á, »ý½Ä ÀÇ·á ½ºÅ©¸®´×À» À§ÇØ À¯Àüü ÀλçÀÌÆ®¸¦ Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. Á¾¾çÇÐÀº ÁÖ¿ä ÁßÁ¡ ºÐ¾ßÀ̸ç, À¯ÀüÀÚ °Ë»ç¸¦ ÅëÇØ ȯÀÚº° À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ¿¡ ±â¹ÝÇÑ Ç¥Àû ¾Ï Ä¡·á¸¦ À¯µµÇÕ´Ï´Ù. ¶ÇÇÑ Èñ±ÍÁúȯÀÇ À¯ÀüÀÚ °Ë»ç, »êÀü °Ë»ç, ¾à¹°À¯ÀüüÇÐÀº Á¶±â Áø´Ü°ú Ä¡·á °èȹÀ» Å©°Ô Çâ»ó½ÃÄ×½À´Ï´Ù.

³ó¾÷ ºÐ¾ß¿¡¼­´Â À¯ÀüÀÚ ºÐ¼®ÀÌ ÀÛ¹° °³·®°ú °¡Ãà À°Á¾¿¡ ÀÖÀ¸¸ç, ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¬±¸ÀÚµéÀº ¼öÈ®·®, ³»º´¼º, ȯ°æ ÀûÀÀ¼º°ú °ü·ÃµÈ À¯ÀüÀÚ¸¦ ã¾Æ³»¾î À¯ÀüÀÚÀûÀ¸·Î ÃÖÀûÈ­µÈ ÀÛ¹°À» °³¹ßÇÔÀ¸·Î½á ¼¼°è ½Ä·®¾Èº¸ ¹®Á¦¸¦ ÇØ°áÇϰí ÀÖ½À´Ï´Ù. »ý¸í°øÇÐ ¹× Á¦¾à¾÷°èµµ ½Å¾à°³¹ß, À¯ÀüÀÚ Ä¡·á ¿¬±¸, ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ºÐ¼®À» À§ÇØ À¯ÀüÀÚ ºÐ¼®À» Ȱ¿ëÇϰí ÀÖ½À´Ï´Ù. ½ÃÄö½Ì ±â¼ú°ú AI¸¦ Ȱ¿ëÇÑ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ Áö¼ÓÀûÀÎ ¹ßÀüÀ¸·Î À¯ÀüÀÚ ºÐ¼®Àº ¿¬±¸ ¹× »ó¾÷Àû ÀÀ¿ë¿¡ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ ºÐ¼®ÀÇ Ãֽбâ¼ú Çõ½ÅÀº ¹«¾ùÀΰ¡?

À¯ÀüÀÚ ºÐ¼®ÀÇ ±â¼ú Çõ½ÅÀ¸·Î ½ÃÄö½Ì Á¤È®µµ, µ¥ÀÌÅÍ Ã³¸® ¼Óµµ, ºñ¿ë È¿À²¼ºÀÌ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ´ÜÀÏ ¼¼Æ÷ ½ÃÄö½ÌÀÇ °³¹ß·Î °úÇÐÀÚµéÀº ¼¼Æ÷ ¼öÁØ¿¡¼­ À¯ÀüÀÚ º¯À̸¦ ºÐ¼®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú°í, ¾Ï Áø´Ü°ú ½Å°æ°úÇÐ ¿¬±¸¸¦ °³¼±ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½ºÀÇ AI¿Í ¸Ó½Å·¯´×ÀÇ ÅëÇÕÀ¸·Î À¯Àüü ÁÖ¼®, º¯ÀÌ ÇØ¼®, Áúº´ À§Çè ¿¹ÃøÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

PacBio¿Í Oxford Nanopore¿Í °°Àº ·Õ ¸®µå ½ÃÄö½Ì ±â¼úÀº º¹ÀâÇÑ À¯Àüü ±¸Á¶¿¡ ´ëÇÑ º¸´Ù Á¾ÇÕÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÔÀ¸·Î½á À¯ÀüÀÚ ºÐ¼® ´É·ÂÀ» ´õ¿í È®Àå½ÃÄ×½À´Ï´Ù. CRISPR ±â¹Ý À¯ÀüÀÚ ÆíÁý°ú ÇÕ¼º»ý¹°ÇÐÀÇ ¹ßÀüÀº À¯ÀüÀÚ ºÐ¼®À» º¸¿ÏÇÏ¿© ¿¬±¸ÀÚµéÀÌ DNA ¿°±â¼­¿­À» Á¤¹ÐÇÏ°Ô º¯ÇüÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. À¯ÀüÀÚ ¿¬±¸°¡ °è¼Ó ¹ßÀüÇϰí ÀÖ´Â °¡¿îµ¥, ÀÌ·¯ÇÑ Çõ½ÅÀº Â÷¼¼´ë Áø´Ü, Ä¡·á, ³ó¾÷ÀÇ Çõ½ÅÀ» ÃËÁøÇÒ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

À¯ÀüÀÚ ºÐ¼® ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

À¯ÀüÀÚ ºÐ¼® ½ÃÀåÀÇ ¼ºÀåÀº Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, NGS ±â¼ú äÅ÷ü Áõ°¡, ³ó¾÷ ¹× »ý¸í°øÇÐ ºÐ¾ß¿¡¼­ÀÇ Àû¿ë È®´ë µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. DNA ¿°±â¼­¿­ ºÐ¼® ºñ¿ëÀÌ ³·¾ÆÁö¸é¼­ À¯ÀüÀÚ ºÐ¼®ÀÌ ´õ¿í Ä£¼÷ÇØÁ³°í, ´ë±Ô¸ð Áý´Ü À¯ÀüüÇÐ ÇÁ·ÎÁ§Æ®¿Í °³ÀÎ ¸ÂÃãÇü ÇコÄɾ ´ëÇÑ Á¢±ÙÀÌ °¡´ÉÇØÁ³½À´Ï´Ù. ¶ÇÇÑ À¯Àüü ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÚ±Ý Áö¿ø°ú ¹Î°£ÀÇ ÅõÀÚ·Î ÀÎÇØ ±â¼úÀÇ ¹ßÀü°ú »ó¾÷Àû µµÀÔÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

À¯Àü¼º Áúȯ°ú ¾ÏÀÇ À¯º´·ü Áõ°¡´Â À¯ÀüÀÚ °Ë»ç¿Í Á¶±â Áø´ÜÀÇ Çʿ伺À» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù. ¼ÒºñÀÚµéÀÌ ÀÚ½ÅÀÇ °Ç°­ »óÅÂ, °¡°è, »ýȰ½À°ü ¼ÒÀο¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ¿øÇϹǷΠ¼ÒºñÀÚ Á÷Á¢ À¯ÀüÀÚ °Ë»ç ½ÃÀåµµ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ À¯ÀüÀÚ µ¥ÀÌÅÍ ºÐ¼®¿¡ Ŭ¶ó¿ìµå ÄÄÇ»ÆÃ°ú AIÀÇ ÅëÇÕÀ¸·Î È¿À²¼º°ú È®À强ÀÌ Çâ»óµÇ¾î ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ºÐ¼®ÀÌ ¿©·¯ »ê¾÷¿¡¼­ ÇʼöÀûÀÎ Åø·Î ÀÚ¸® ÀâÀ¸¸é¼­ ±× äÅÃÀº °è¼Ó È®´ëµÉ °ÍÀ̸ç, À¯ÀüüÇÐÀÌ ÁÖµµÇÏ´Â Çõ½Å°ú ¸ÂÃãÇü ÀÇ·áÀÇ ¹Ì·¡¸¦ Çü¼ºÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ºÎ¹®

Á¦Ç°(½Ã¾à¡¤Å°Æ®, ±â±â, ¼ÒÇÁÆ®¿þ¾î), °Ë»ç(À¯ÀüÇÐÀû ¿¹Ãø, ij¸®¾î, Ãâ»ýÀü¡¤½Å»ý¾Æ, Áúȯ Áø´Ü, ÆÄ¸¶ÄÚ°Ô³ð, ±âŸ), ±â¼ú(Â÷¼¼´ë ½ÃÄö½º ±â¼ú, ½Ç½Ã°£ PCR ½Ã½ºÅÛ ±â¼ú, ±âŸ ±â¼ú), ¿ëµµ(¾Ï, À¯ÀüÀÚ Áúȯ, ¼øÈ¯±â Áúȯ, Èñ±ÍÁúȯ, °¨¿°Áõ, ±âŸ), ÃÖÁ¾ ¿ëµµ(º´¿ø, ¿¬±¸°³¹ß ¿¬±¸¼Ò, Áø´Ü ¼¾ÅÍ, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI Åø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM³ª ¾÷°èº° SLM Äõ¸®¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»ç ¼ÒÀçÁö, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±âÁØÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÔ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº Ç϶ô, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Genetic Analysis Market to Reach US$16.5 Billion by 2030

The global market for Genetic Analysis estimated at US$11.6 Billion in the year 2024, is expected to reach US$16.5 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Reagents & Kits, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$9.4 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.2 Billion While China is Forecast to Grow at 9.6% CAGR

The Genetic Analysis market in the U.S. is estimated at US$3.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2030 trailing a CAGR of 9.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Genetic Analysis Market - Key Trends & Drivers Summarized

Why Is Genetic Analysis Revolutionizing Healthcare and Scientific Research?

Genetic analysis has transformed healthcare, agriculture, and biomedical research by providing critical insights into DNA sequences, genetic variations, and disease predisposition. Advances in next-generation sequencing (NGS), polymerase chain reaction (PCR), and microarray technologies have enabled researchers to decode genetic information with unprecedented accuracy and speed. These techniques allow for the identification of hereditary diseases, early cancer detection, and personalized medicine approaches, revolutionizing patient care and disease management.

Beyond healthcare, genetic analysis plays a crucial role in forensic science, evolutionary biology, and agriculture. In forensic investigations, DNA profiling has enhanced crime-solving capabilities, while in agriculture, genetic analysis has facilitated the breeding of high-yield, disease-resistant crops. The increasing accessibility of direct-to-consumer (DTC) genetic testing has also driven market growth, allowing individuals to gain insights into their ancestry, health risks, and inherited traits. As the applications of genetic analysis continue to expand, the demand for high-throughput sequencing and bioinformatics solutions is rising across multiple industries.

Which Industries Are Driving the Demand for Genetic Analysis?

The healthcare sector is the largest consumer of genetic analysis technologies, leveraging genomic insights for disease risk assessment, precision medicine, and reproductive health screening. Oncology has been a primary focus area, with genetic tests guiding targeted cancer therapies based on a patient’s unique genetic profile. Additionally, genetic screening for rare diseases, prenatal testing, and pharmacogenomics has significantly improved early diagnosis and treatment planning.

In agriculture, genetic analysis is playing a pivotal role in crop improvement and livestock breeding. By identifying genes associated with yield, disease resistance, and environmental adaptability, researchers are developing genetically optimized crops to address global food security challenges. The biotechnology and pharmaceutical industries also rely on genetic analysis for drug discovery, gene therapy research, and microbiome analysis. With continuous advancements in sequencing technologies and AI-driven bioinformatics, genetic analysis is becoming an integral part of research and commercial applications.

What Are the Latest Technological Innovations in Genetic Analysis?

Technological innovations in genetic analysis have significantly enhanced sequencing accuracy, data processing speed, and cost-effectiveness. The development of single-cell sequencing has enabled scientists to analyze genetic variations at the cellular level, improving cancer diagnostics and neuroscience research. Additionally, the integration of AI and machine learning in bioinformatics has accelerated genome annotation, variant interpretation, and disease risk prediction.

Long-read sequencing technologies, such as PacBio and Oxford Nanopore, have further expanded the capabilities of genetic analysis by providing more comprehensive insights into complex genomic structures. Advances in CRISPR-based gene editing and synthetic biology are also complementing genetic analysis, allowing researchers to modify DNA sequences with high precision. As genetic research continues to evolve, these innovations are expected to drive the next generation of diagnostic, therapeutic, and agricultural breakthroughs.

What Factors Are Fueling the Growth of the Genetic Analysis Market?

The growth in the genetic analysis market is driven by several factors, including increasing demand for precision medicine, rising adoption of NGS technologies, and expanding applications in agriculture and biotechnology. The declining cost of DNA sequencing has made genetic analysis more accessible, enabling large-scale population genomics projects and personalized healthcare initiatives. Additionally, government funding and private investments in genomic research have accelerated technological advancements and commercial adoption.

The growing prevalence of genetic disorders and cancer has further increased the need for genetic screening and early diagnostics. The direct-to-consumer genetic testing market is also expanding, as consumers seek insights into their health, ancestry, and lifestyle predispositions. Moreover, the integration of cloud computing and AI in genetic data analysis has improved efficiency and scalability, driving market expansion. As genetic analysis becomes an essential tool across multiple industries, its adoption is expected to continue growing, shaping the future of genomics-driven innovation and personalized medicine.

SCOPE OF STUDY:

The report analyzes the Genetic Analysis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Reagents & Kits, Instruments, Software); Test (Predictive Genetic Testing, Carrier Testing, Prenatal & Newborn Testing, Disease Diagnostic Testing, Pharmacogenomic Testing, Other Tests); Technology (Next-Generation Sequencing Technology, Real-Time PCR System Technology, Other Technologies); Application (Cancer Application, Genetic Diseases Application, Cardiovascular Diseases Application, Rare Diseases Application, Infectious Diseases Application, Other Applications); End-Use (Hospitals End-Use, Research & Development Laboratories End-Use, Diagnostic Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â